HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 277, Issue 12, 10678-10682, March 22, 2002

This Article Abstract Full Text (PDF) All Versions of this Article: 277/12/10678    most recent M111369200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holstein, S. A. Articles by Hohl, R. J. Search for Related Content PubMed PubMed Citation Articles by Holstein, S. A. Articles by Hohl, R. J. Social Bookmarking                      What's this?

Consequences of Mevalonate Depletion

DIFFERENTIAL TRANSCRIPTIONAL, TRANSLATIONAL, AND POST-TRANSLATIONAL UP-REGULATION OF Ras, Rap1a, RhoA, AND RhoB^*

Sarah A. Holstein, Christine L. Wohlford-Lenane^§, and Raymond J. Hohl^¶

From the Departments of  Pharmacology and ^§ Internal Medicine, University of Iowa, Iowa City, Iowa 52242

Received for publication, November 28, 2001, and in revised form, December 18, 2001

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Ras-related proteins are small GTPases that are post-translationally modified with mevalonate-derived isoprenoids. Although the effects of inhibition of isoprenylation on protein function have been examined, the consequences of depletion of isoprenoid pools on regulation of expression of isoprenylated proteins have yet to be investigated. In these studies we have shown that depletion of mevalonate results in increased total levels of Ras, Rap1a, RhoA, and RhoB in K562 cells. Cycloheximide and [³⁵S]methionine pulse/pulse-chase experiments reveal that mevalonate depletion increases the de novo synthesis of Ras and RhoA and decreases the degradation of existing Ras and RhoA protein. Pretreatment with actinomycin D completely prevents the induced up-regulation of RhoB and only partially prevents the up-regulation of Ras, Rap1a, and RhoA. Although depletion of mevalonate does not alter steady state levels of Ras mRNA, there is an increase in RhoB mRNA. Our results are the first to demonstrate that mevalonate depletion induces up-regulation of Ras and Ras-related proteins by discrete mechanisms that include modulation of transcriptional, translational, and post-translational processes.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Members of the Ras protein superfamily, including Ras, Rap1a, and the Rho proteins, are membrane-bound small GTPases that cycle between an active GTP-bound state and an inactive GDP-bound state. These proteins influence fundamental cellular processes. For example, Ras plays a central role in signal transduction pathways regulating cell survival, proliferation, and differentiation (1). Rap1a has been shown to act as a negative regulator of Ras by binding to Ras effector proteins such as Raf-1, thus preventing Ras-induced Raf-1 activation (2). RhoA has been implicated as having a key role in regulating cytoskeletal organization (3, 4). The physiological function of RhoB remains largely unclear. RhoB knock-out mice do not exhibit developmental defects, diminished fertility, or impaired wound healing; however, there is abnormality in fibroblast motility (5). For these proteins, proper membrane association is believed to be necessary for normal function (6-8).

The Ras-related proteins become membrane-associated after undergoing a series of post-translational modifications, the first of which involves the addition of a 15-carbon farnesyl or a 20-carbon geranylgeranyl chain to a cysteine residue at the carboxyl terminus. Ras proteins are generally farnesylated (9), whereas Rap1a and RhoA are geranylgeranylated (10, 11). RhoB may be either farnesylated or geranylgeranylated (12, 13). These isoprenylation reactions are catalyzed by the enzymes farnesyl transferase and geranylgeranyl transferase I, and the isoprenoid substrates in these reactions are derived from mevalonate. Addition of the lipid chain to the protein serves to anchor the protein to the membrane (6). It is generally believed that isoprenylation is required for the proteins to exert their biological effects; however, there is evidence to suggest that unmodified versions may also have functional effects (14, 15). These effects were observed in studies involving overexpression of mutant Rho proteins that could not be isoprenylated. Although there is substantial understanding of the results of inhibition of post-translational modification of these proteins, little is known of the effects of altered levels of these proteins on cell processes.

Statins competitively inhibit HMG-CoA reductase, the enzyme that converts HMG-CoA¹ to mevalonate (16). Depletion of mevalonate is known to alter the expression of key proteins involved in isoprene metabolism, most notably HMG-CoA reductase. The level of HMG-CoA reductase is under multivalent control at both transcriptional and post-transcriptional sites, and this regulation is dependent on both sterol and non-sterol components of the cholesterol biosynthetic pathway (17-20). We and others have used statins as a tool to impair protein prenylation because depletion of mevalonate results in depletion of farnesyl pyrophosphate and geranylgeranyl pyrophosphate (21-23). The consequences of this impairment, or perhaps more appropriately, of mevalonate depletion on isoprenylated protein expression have not previously been investigated. To further understand the consequences of mevalonate depletion on expression of the small GTPases that are normally isoprenylated we have investigated the effects of mevalonate depletion on Ras, Rap1a, RhoA, and RhoB expression.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Cell Cultures and Reagents-- The K562 cell line was purchased from the American Type Culture Collection (Manassas, VA). The K562 cell line is a human erythroleukemia line that was established from a patient with chronic myelogenous leukemia (24). K562 cells were grown in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, penicillin/streptomycin, amphotericin (2.5 µg/ml), and glutamine (2 mM). Cells were grown at 37 °C and 5% CO₂ in T-75 culture flasks. Anti-RhoA, anti-RhoB, anti-Rap1A, anti--tubulin, and anti-goat IgG horseradish peroxidase antibodies as well as agarose-conjugated RhoA and actin antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The NCC-004 anti-pan Ras antibody (25) was kindly provided by Dr. Setsuo Hirohashi (National Cancer Center, Tokyo). Anti-v-Ha-Ras (Ab-1, pan Ras)-agarose conjugate was obtained from Calbiochem (San Diego, CA). Anti-mouse and anti-rabbit horseradish peroxidase-linked antibodies were obtained from Amersham Biosciences, Inc. ³⁵S-Express protein labeling mix was purchased from PerkinElmer Life Sciences. Methionine- and cystine-deficient RPMI medium was obtained from ICN (Costa Mesa, CA).

Western Blot Analysis-- Cells were incubated with lovastatin for 0-24 h. For actinomycin D and cycloheximide experiments, cells were treated with actinomycin D or cycloheximide for 1 h prior to the addition of lovastatin. Cells were then collected at 2-h intervals, washed with phosphate-buffered saline, and lysed in RIPA buffer (0.15 M NaCl, 1% sodium deoxycholate, 0.1% SDS, 1% Triton (v/v) X-100, 0.05 M Tris-HCl) containing protease inhibitors (phenylmethylsulfonyl fluoride and aprotinin) and sodium orthovanadate. Protein content was determined using the Lowry method (26). Equivalent amounts of cell lysate were resolved by SDS-PAGE, transferred to polyvinylidene difluoride membrane, and probed with the appropriate antibodies. Blots probed for Ras, RhoA, RhoB, Rap1A, and -tubulin were detected with horseradish peroxidase-linked secondary antibodies and ECL Western blotting reagents (Amersham Biosciences, Inc.) according the to manufacturer's protocols.

[³⁵S]Methionine Experiments-- For pulse experiments, cells were incubated with or without lovastatin for 4, 8, 12, and 24 h and were pulsed with [³⁵S]methionine during the last 4 h of each incubation. For pulse-chase experiments, cells were preincubated in methionine- and cystine-free RPMI medium with 2% fetal calf serum for 1 h and then pulsed with [³⁵S]methionine (120 µCi/ml) for 4 h. Cells were then washed with complete RPMI medium plus 10 mM methionine, 3 mM cysteine, and 10% fetal calf serum and incubated for 0-24 h in the presence or absence of lovastatin and/or mevalonate. Cells were lysed in RIPA buffer, and following preclearing, 200 µg of whole cell lysate was diluted in RIPA + 1% bovine serum albumin and incubated with agarose-conjugated antibodies at 4 °C. Ras, RhoA and actin immunocomplexes were obtained per the manufacturers' protocols. Immunocomplexes were washed with RIPA + 1% bovine serum albumin and 1× phosphate-buffered saline + 1% bovine serum albumin. The pellets were fractionated by SDS-PAGE, and dried gels were exposed to film at 70 °C. The radioactivity of excised bands was determined using liquid scintillation counting.

Preparation and Synthesis of RNA Probe Templates-- All RNA probes used in this study were generated in our laboratory using reverse transcriptase-polymerase chain reaction with the addition of an RNA polymerase site (Lig'nScribe, Ambion, Austin, TX) to the RT-PCR product. A 560-bp human RhoB cDNA was generated using the following primer sets: TCA TAG CAC CTT GCA GCA GTT and TCA TTG ATC GGG AGA CGT G. A 194-bp human Ha-Ras cDNA was generated using the following primer sets: ACG TCA TCC GAG TCC TTC AC and TCA TTG ATG GGG AGA CGT G. A 250-bp human N-Ras cDNA was generated using the following primer sets: AGA TTT CGG GAG GGA TGA AG AND GAC CTG ATC GGT TGG TCA AT. An additional 60-bp was added to all of the above templates when the T7 RNA polymerase site was added to the cDNA using the Lig'nScribe RNA Polymerase Promoter Addition Kit (Ambion). Each probe template was sequenced using a ABI Prism Genetic Analyzer (PerkinElmer Life Sciences) prior to use.

Preparation of RNA and Northern Blot Analysis-- Total RNA was isolated from cells using the single-step method (27), lysing the cells in 1.2 ml of Trizol Reagent (Invitrogen). Chloroform was added and the total RNA precipitated from the aqueous phase by the addition of isopropyl alcohol, the RNA pellet washed with ethanol and solubilized in RNase free water. The yield and purity of the total RNA were quantitated by measuring the ratio of the absorbance at 260 and 280 nm. RNA integrity was determined by examining the 28 and 18 S rRNA bands on a 1.2% agarose, 2.2 M formaldehyde gel. Total RNA (20 µg) was separated on a 1.2% agarose, 2.2 M formaldehyde gel, transferred to Hybond-N+ (Amersham Life Sciences, Inc.) membrane by capillary action overnight and UV-crosslinked. The RNA containing membranes were prehybridized at 68 °C for 5 h in UltraHyb Hybridization Buffer (Ambion). The ³²P-labeled antisense riboprobe, at a concentration of 1 × 10⁶ cpm/ml, was added to the hybridization buffer, and the blots were hybridized overnight at 68 °C. The blots were then washed twice in 2× SSC, 0.1% SDS at 68 °C for 5 min each followed by two washes in 0.1× SSC, 0.1% SDS at 68 °C. The blots were then exposed to x-ray film at 70 °C.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Mevalonate Depletion Increases Ras and Ras-related Protein Levels-- The effect of mevalonate depletion on total levels of Ras, Rap1a, RhoA, and RhoB was examined via Western blot analysis. K562 cells were incubated with 10 µM lovastatin for 0-24 h with cells collected for Western blot analysis at 2-h intervals. As shown in Fig. 1, there was an increase in the levels of Ras, RhoA, RhoB, and Rap1a over time. For Ras this effect could be observed after only 2 h of incubation with lovastatin, as indicated by the appearance of the more slowly migrating band in the Ras immunoblot signifying unmodified Ras protein. By 24 h there was a 2-fold increase in the total amount of Ras present. RhoA levels increased to approximately 4-fold by 24 h. Although unmodified Rap1a could not be detected under control conditions, it was detectable after 2 h of lovastatin treatment, and levels increased over 24 h. RhoB levels increased significantly from 10 to 24 h (at least 5-fold) as compared with control. As a control, it was shown that lovastatin did not alter -tubulin levels.

View larger version (38K): [in this window] [in a new window]   Fig. 1.   Mevalonate depletion increases Ras and Ras-related protein levels. K562 cells were incubated with 10 µM lovastatin for up to 24 h with cells collected every 2 h. These immunoblots were developed as described under "Experimental Procedures." Each lane contains an equivalent amount of protein from cell lysate. The blots reflect one study that is representative of three independent experiments.

Role of New Protein Synthesis in the Up-regulation of Ras and Ras-related Proteins-- To determine whether the increases in Ras, RhoA, RhoB, and Rap1a levels induced by mevalonate depletion were dependent on the synthesis of new protein, cells were pretreated with the protein synthesis inhibitor cycloheximide (28) prior to incubation with lovastatin. As shown in Fig. 2, pretreatment with cycloheximide (1.4 µg/ml) completely blocked mevalonate depletion-induced up-regulation of RhoA and RhoB and partially blocked the increase in Ras and Rap1a. Higher concentrations of cycloheximide (10 µg/ml or 20 µg/ml) further reduced the increase in Ras and Rap1a levels (data not shown). Treatment with cycloheximide alone did not significantly alter the levels of Ras, RhoA, or tubulin. As with untreated cells, unmodified Rap1a was not detected in cells treated with cycloheximide, and RhoB was minimally detected.

View larger version (32K): [in this window] [in a new window]   Fig. 2.   Effects of pretreatment with cycloheximide on up-regulation of Ras and Ras-related proteins induced by mevalonate depletion. K562 cells were pretreated with cycloheximide (1.4 µg/ml) for 1 h prior to the addition of lovastatin. Cells were collected every 2 h. These immunoblots were developed as described under "Experimental Procedures." Each lane contains an equivalent amount of protein from cell lysate. The results are representative of two independent experiments.

To more carefully examine the effects of mevalonate depletion on de novo synthesis of isoprenylated proteins, experiments were performed in which cells were labeled with [³⁵S]methionine. Cells were incubated with or without 10 µM lovastatin for 4, 8, 12, and 24 h. Cells were pulsed with [³⁵S]methionine (120 µCi/10 × 10⁶ cells) during the last 4 h of each incubation, and Ras, RhoA, and actin were immunoprecipitated. As shown in Fig. 3, A and B, incubation with lovastatin increased the amount of newly synthesized Ras and RhoA at each time point compared with control cells. In addition, as seen by the presence of the more slowly migrating band, the ³⁵S-labeled Ras population in mevalonate-depleted cells was composed solely of unmodified Ras. As a control, synthesis of actin was examined, and it was found that depletion of mevalonate did not alter the level of ³⁵S-labeled actin (Fig. 3C). Trichloroacetic acid precipitation studies revealed that the incorporation of [³⁵S]methionine into total protein pools was not significantly altered by treatment with lovastatin (data not shown).

View larger version (22K): [in this window] [in a new window]   Fig. 3.   Mevalonate depletion increases de novo synthesis of Ras and RhoA. K562 cells were incubated with or without lovastatin (10 µM) for 4, 8, 12, and 24 h. Cells were pulsed with [35S]methionine (120 µCi/10 × 106 cells) during the last 4 h of each incubation. Ras (A), RhoA (B), and actin (C) were immunoprecipitated, fractionated on SDS-PAGE, and exposed to film at 70 °C for 2-5 days. Representative gels from duplicate experiments are displayed. Bands were subsequently excised and radiolabel counted via liquid scintillation counting. For Ras and RhoA the counts are displayed in bar graph format. The solid bars represent radiolabel under control conditions, and the open bars reflect radiolabel from cells incubated with lovastatin.

Role of Protein Turnover in the Up-regulation of Ras and Ras-related Proteins-- Pulse-chase experiments were performed to determine whether mevalonate depletion, in addition to increasing the synthesis of Ras and RhoA, also affected their degradation. Cells were pulsed with [³⁵S]methionine for 4 h and then chased for 0, 4, 8, 16, and 24 h. As shown in Fig. 4A, there was a decline in labeled Ras over 24 h. Mevalonate depletion decreased the degradation of labeled Ras. On the basis of these experiments, the half-life of Ras was estimated to be 19 h under control conditions and 30 h in lovastatin-treated cells. Depletion of mevalonate also decreased the rate of degradation of RhoA (Fig. 4B). The half-life of RhoA was also found to be prolonged from ~24 h in control cells to 34 h in lovastatin-treated cells. As a control, the degradation of actin was examined, and it was found that mevalonate depletion did not alter the half-life of actin (Fig. 4C). The loss of ³⁵S from total protein pools over time in the pulse-chase experiments was not affected by incubation with lovastatin (data not shown).

View larger version (22K): [in this window] [in a new window]   Fig. 4.   The rate of degradation of Ras and RhoA is decreased by mevalonate depletion. K562 cells were pulsed with [35S]methionine (120 µCi/ml) for 4 h and then chased in the absence or presence of lovastatin (10 µM). Ras (A), RhoA (B), and actin (C) were immunoprecipitated, fractionated on SDS-PAGE, and exposed to film at 70 °C for 3-5 days. Bands were subsequently excised and counted via liquid scintillation counting. For Ras and RhoA the counts are expressed as a percentage of the radioactivity at the conclusion of the pulse and are displayed in semi-log plots. The results are representative of two independent experiments.

Reversal of Lovastatin-induced Changes by Mevalonate-- To verify that the effects of lovastatin on protein synthesis and degradation were due to depletion of mevalonate, pulse and pulse-chase experiments were performed with or without the addition of mevalonate. For the pulse experiments, cells were incubated for 24 h with lovastatin (10 µM) and/or mevalonate (5 mM) and pulsed with [³⁵S]methionine during the last 4 h of the incubation. As shown in Fig. 5A, coincubation of mevalonate prevented the lovastatin-induced increase in [³⁵S]methionine incorporation into newly synthesized Ras and RhoA. Treatment with mevalonate alone did not alter the level of labeled Ras or RhoA. Pulse-chase experiments were also performed in which cells were pulsed for 4 h with [³⁵S]methionine and then chased for 24 h in the presence of lovastatin and/or mevalonate. Coincubation with mevalonate prevented the lovastatin-induced alteration in Ras and RhoA degradation (Fig. 5B). As a control, the effects of lovastatin and/or mevalonate on actin synthesis and degradation were also examined, and no differences were observed.

View larger version (53K): [in this window] [in a new window]   Fig. 5.   Coincubation with mevalonate prevents lovastatin-induced changes in Ras and RhoA synthesis and degradation. A, K562 cells were incubated with 10 µM lovastatin (Lov) and/or 5 mM mevalonate (Mev) for 24 h and pulsed with [35S]methionine during the last 4 h. B, cells were pulsed with [35S]methionine for 4 h and then chased for 24 h in the presence of lovastatin and/or mevalonate. Ras, RhoA, and actin were immunoprecipitated as described under "Experimental Procedures." Control cells were incubated without drugs. The results are representative of two independent experiments.

Dependence of Protein Up-regulation on Pretranslational Events-- To determine whether protein up-regulation by mevalonate depletion requires new mRNA synthesis, cells were pretreated with actinomycin D, an inhibitor of transcription. As shown in Fig. 6, pretreatment with actinomycin D (0.5 µg/ml) prevented the increase in RhoB levels and partially blocked the up-regulation of Ras, Rap1a, and RhoA induced by mevalonate depletion. As a control, cells were also incubated with actinomycin D alone, and no changes were observed.

View larger version (32K): [in this window] [in a new window]   Fig. 6.   Effects of pretreatment with actinomycin D on up-regulation of Ras and Ras-related proteins induced by mevalonate depletion. K562 cells were pretreated with actinomycin D (0.5 µg/ml) for 1 h prior to addition of lovastatin. Cells were collected every 2 h. These immunoblots were developed as described under "Experimental Procedures." Each lane contains an equivalent amount of protein from cell lysate. Representative gels from duplicate experiments are displayed.

To further examine the effects of mevalonate depletion on transcription, Northern blot analyses were performed. As shown in Fig. 7, incubation with lovastatin for 0-24 h did not alter the steady state levels of Ha-Ras or N-Ras mRNA. Unlike Ha-Ras and N-Ras, however, depletion of mevalonate did alter RhoB mRNA levels. As demonstrated in Fig. 7, there was a progressive increase in RhoB mRNA levels with this depletion. The increase in RhoB message was completely blocked by pretreatment with actinomycin D (data not shown).

View larger version (111K): [in this window] [in a new window]   Fig. 7.   Effects of mevalonate depletion on Ha-Ras, N-Ras, and RhoB mRNA levels. K562 cells were incubated with 10 µM lovastatin for up to 24 h. Total RNA was isolated, fractionated on a 1.2% agarose, 2.2 M formaldehyde gel, transferred to membrane, and probed with Ha-Ras-, N-Ras-, or RhoB-specific riboprobes as described under "Experimental Procedures." The lower panel depicts an ethidium bromide-stained gel.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

For many years it has been recognized that depletion of mevalonate by inhibition of HMG-CoA reductase alters the post-translational processing of CAAX-containing small GTPase proteins (21, 22). We have provided the first evidence demonstrating that mevalonate depletion alters the regulation of expression of CAAX proteins. In this context, there are relatively limited prior publications with which to integrate our findings. Fig. 1 clearly reveals temporal differences in the overall up-regulation of Ras, Rap1a, RhoA, and RhoB. For example, increases in total Ras and Rap1a levels are observed as early as 2 h, whereas increases in RhoB are not apparent until 10 h after the addition of lovastatin. These temporal differences of early versus late up-regulation of protein levels support the hypothesis that isoprenylated proteins are not uniformly regulated in response to mevalonate depletion. Our studies demonstrate that such depletion of mevalonate results in the up-regulation of isoprenylated proteins via discrete mechanisms including transcription, translation, and post-translational degradation.

The cycloheximide experiments (Fig. 2) reveal that new protein synthesis is required for RhoA and RhoB and to a lesser extent for Ras and Rap1a up-regulation in response to mevalonate depletion. Support for these findings also includes the [³⁵S]methionine pulse studies (Fig. 3, A and B) in which mevalonate depletion increases ³⁵S incorporation into immunoprecipitable Ras and RhoA. It is of interest that although up-regulation of Ras occurs earlier than that of RhoA (Fig. 1), the increased incorporation of [³⁵S]methionine into Ras and RhoA in lovastatin-treated cells is similar at early time points (Fig. 3).

[³⁵S]Methionine pulse-chase experiments (Fig. 4) reveal that mevalonate depletion lengthens the t_1/2 of both Ras and RhoA. For these proteins the t_1/2 was similarly prolonged by ~58% for Ras and 42% for RhoA. Because base-line levels of RhoB are only minimally-detectable, it is not possible to determine the effects of mevalonate depletion on protein half-life in this system. There has been very limited data published on the t_1/2 or regulation of production/degradation of these small GTPases. That the t_1/2 for Ras in K562 cells is estimated at 19 h (Fig. 4A) is in agreement with the t_1/2 of 20 h for Ras described in transfected NIH-3T3 cells (29). In these latter cells the t_1/2 of Ras may have been in part correlated with its phosphorylation state. Similarly, the t_1/2 for RhoA in K562 cells is estimated at 24 h (Fig. 4B). This is in relative agreement with the reported t_1/2 for RhoA of 31 h, albeit in RAW264 cells (30). In these cells the t_1/2 for RhoA appeared to be decreased to 12 h with carboxyl methylation inhibition. Although the prior studies describing the t_1/2 for Ras and RhoA implicated phosphorylation and carboxyl methylation as being important, the basis for the t_1/2 regulation was not explored. Our studies of K562 cells implicate the mevalonate-derived isoprenoid pool as also contributing to the degradation of these proteins. It is of interest that the reduction of these isoprenoids decreases the degradation of already isoprenylated Ras and RhoA. This finding suggests regulatory pathways to sustain levels of isoprenylated Ras and RhoA under conditions that would otherwise limit protein isoprenylation.

Recent studies have indicated that lovastatin may have additional functions independent of its inhibition of HMG-CoA reductase (31, 32). For example, lovastatin binds to the I domain of ₁₂ integrin and thus blocks the interaction of this integrin with ICAM-1 (intercellular adhesion molecule 1) (33, 34). This process was not reversed by the addition of mevalonate. Fig. 5 demonstrates that the effects of lovastatin on Ras and RhoA synthesis and degradation are due to inhibition of HMG-CoA reductase. Coincubation of cells with both lovastatin and mevalonate negates the effects of lovastatin.

To further dissect the mechanisms for mevalonate depletion-induced up-regulation of proteins, studies were performed utilizing actinomycin D. Fig. 6 displays that inhibition of DNA-dependent RNA polymerase completely abrogates the increase in RhoB protein observed with lovastatin (Fig. 1). For Ras, Rap1a, and RhoA, pretreatment with actinomycin D diminishes lovastatin-induced up-regulation. Message levels of Ras and RhoB were examined because of the differential responses of Ras and RhoB with regard to timing of up-regulation and effect of actinomycin D. Fig. 7 demonstrates that mevalonate depletion does not significantly alter steady state mRNA levels of Ha-Ras or N-Ras but does induce a progressive increase in RhoB mRNA. These results suggest an explanation for why the increase in total Ras levels occurs earlier than that of RhoB. The early up-regulation of Ras is less dependent on production of mRNA than is the later occurring up-regulation of RhoB. The timing of the increase in RhoB mRNA coincides with the increase in RhoB protein level. Heretofore relatively little work has been published on the transcriptional regulation of Ras and Ras-related small GTPases. RhoB has been shown to be transcriptionally activated by genotoxic stress mediated via a CCAAT element (35). In addition, sequence analysis of the rhoB promoter identifies TATA, Sp1, and CAAT box elements and AP-2, AP-4, and p53 consensus sequences (36). The interaction of mevalonate-derived isoprenoids with these binding sequences or with their associated transcription factors has yet to be investigated. Master transcriptional regulators of cholesterol biosynthesis influence HMG-CoA reductase expression (37). These studies provide potential targets for additional investigation directed toward understanding the influence of mevalonate depletion on expression of Ras-related proteins.

In summary, while mevalonate depletion is known to up-regulate some proteins such as HMG-CoA reductase, our studies are the first to reveal that such depletion induces the up-regulation of Ras, Rap1a, RhoA, and RhoB. Mechanisms underlying this up-regulation are shown to be increased mRNA synthesis, increased protein synthesis, and decreased protein degradation. Interestingly, the relative contribution of these discrete mechanisms to the up-regulation differs among these Ras-related proteins. Because mevalonate depletion results in a decrease in the levels of farnesyl pyrophosphate and geranylgeranyl pyrophosphate, one might hypothesize that this depletion might similarly alter the levels of farnesylated and geranylgeranylated proteins. Although there is similar up-regulation of farnesylated (Ras, RhoB) and geranylgeranylated (Rap1a, RhoA, RhoB) proteins, the mechanism for the up-regulation differs for proteins both within and between these two groups. Future studies of the effects of mevalonate-derived isoprenoids will further advance the understanding of the regulatory mechanisms identified by our studies that influence expression of these isoprenylated proteins.

	FOOTNOTES

^* This project was supported by the Leukemia and Lymphoma Society in the form of a translational research grant, the Roy J. Carver Charitable Trust, and the Roland W. Holden Family Program for Experimental Cancer Therapeutics.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^¶ To whom correspondence should be addressed: Dept. of Internal Medicine, C32 GH, University of Iowa, Iowa City, IA 52242. Tel.: 319-356-8110; Fax: 319-353-8383; E-mail: raymond-hohl@uiowa.edu.

Published, JBC Papers in Press, January 11, 2002, DOI 10.1074/jbc.M111369200

	ABBREVIATIONS

The abbreviations used are: HMG-CoA, hydroxymethylglutaryl coenzyme A; RIPA, radioimmune precipitation buffer.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				C. M. Shachaf, O. D. Perez, S. Youssef, A. C. Fan, S. Elchuri, M. J. Goldstein, A. E. Shirer, O. Sharpe, J. Chen, D. J. Mitchell, et al. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis Blood, October 1, 2007; 110(7): 2674 - 2684. [Abstract] [Full Text] [PDF]

				M. Li, Y. Liu, P. Dutt, B. L. Fanburg, and D. Toksoz Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin Am J Physiol Lung Cell Mol Physiol, August 1, 2007; 293(2): L463 - L471. [Abstract] [Full Text] [PDF]

				W. W.-L. Wong, J. W. Clendening, A. Martirosyan, P. C. Boutros, C. Bros, F. Khosravi, I. Jurisica, A. K. Stewart, P. L. Bergsagel, and L. Z. Penn Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma Mol. Cancer Ther., June 1, 2007; 6(6): 1886 - 1897. [Abstract] [Full Text] [PDF]

				Y. Dai, P. Khanna, S. Chen, X.-Y. Pei, P. Dent, and S. Grant Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation Blood, May 15, 2007; 109(10): 4415 - 4423. [Abstract] [Full Text] [PDF]

				S. Camino-Lopez, V. Llorente-Cortes, J. Sendra, and L. Badimon Tissue factor induction by aggregated LDL depends on LDL receptor-related protein expression (LRP1) and Rho A translocation in human vascular smooth muscle cells Cardiovasc Res, January 1, 2007; 73(1): 208 - 216. [Abstract] [Full Text] [PDF]

				H. Okazaki, F. Tazoe, S. Okazaki, N. Isoo, K. Tsukamoto, M. Sekiya, N. Yahagi, Y. Iizuka, K. Ohashi, T. Kitamine, et al. Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver J. Lipid Res., September 1, 2006; 47(9): 1950 - 1958. [Abstract] [Full Text] [PDF]

				E. Cernuda-Morollon and A. J. Ridley Rho GTPases and Leukocyte Adhesion Receptor Expression and Function in Endothelial Cells Circ. Res., March 31, 2006; 98(6): 757 - 767. [Abstract] [Full Text] [PDF]

				S. E. Dunn, S. Youssef, M. J. Goldstein, T. Prod'homme, M. S. Weber, S. S. Zamvil, and L. Steinman Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin J. Exp. Med., February 21, 2006; 203(2): 401 - 412. [Abstract] [Full Text] [PDF]

				S. N. Hamadmad, M. K. Henry, and R. J. Hohl Erythropoietin Receptor Signal Transduction Requires Protein Geranylgeranylation J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 403 - 409. [Abstract] [Full Text] [PDF]

				S. Waiczies, T. Prozorovski, C. Infante-Duarte, A. Hahner, O. Aktas, O. Ullrich, and F. Zipp Atorvastatin Induces T Cell Anergy via Phosphorylation of ERK1 J. Immunol., May 1, 2005; 174(9): 5630 - 5635. [Abstract] [Full Text] [PDF]

				H. Mo and C. E. Elson Studies of the Isoprenoid-Mediated Inhibition of Mevalonate Synthesis Applied to Cancer Chemotherapy and Chemoprevention Experimental Biology and Medicine, July 1, 2004; 229(7): 567 - 585. [Abstract] [Full Text] [PDF]

				F. R. DANESH and Y. S. KANWAR Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy FASEB J, May 1, 2004; 18(7): 805 - 815. [Abstract] [Full Text] [PDF]

				S. Seiler and M. Plamann The Genetic Basis of Cellular Morphogenesis in the Filamentous Fungus Neurospora crassa Mol. Biol. Cell, November 1, 2003; 14(11): 4352 - 4364. [Abstract] [Full Text] [PDF]

				J. Y. Song, J. W. Lim, H. Kim, T. Morio, and K. H. Kim Oxidative Stress Induces Nuclear Loss of DNA Repair Proteins Ku70 and Ku80 and Apoptosis in Pancreatic Acinar AR42J Cells J. Biol. Chem., September 19, 2003; 278(38): 36676 - 36687. [Abstract] [Full Text] [PDF]

				S. A. Holstein and R. J. Hohl Monoterpene regulation of Ras and Ras-related protein expression J. Lipid Res., June 1, 2003; 44(6): 1209 - 1215. [Abstract] [Full Text] [PDF]

				S. M. Houten, M. S. Schneiders, R. J. A. Wanders, and H. R. Waterham Regulation of Isoprenoid/Cholesterol Biosynthesis in Cells from Mevalonate Kinase-deficient Patients J. Biol. Chem., February 14, 2003; 278(8): 5736 - 5743. [Abstract] [Full Text] [PDF]

				K. Stamatakis, E. Cernuda-Morollon, O. Hernandez-Perera, and D. Perez-Sala Isoprenylation of RhoB Is Necessary for Its Degradation. A NOVEL DETERMINANT IN THE COMPLEX REGULATION OF RhoB EXPRESSION BY THE MEVALONATE PATHWAY J. Biol. Chem., December 13, 2002; 277(51): 49389 - 49396. [Abstract] [Full Text] [PDF]

This Article